<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00278174</url>
  </required_header>
  <id_info>
    <org_study_id>CASE15804</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CCF-7752</secondary_id>
    <secondary_id>CASE15804</secondary_id>
    <nct_id>NCT00278174</nct_id>
  </id_info>
  <brief_title>Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer</brief_title>
  <official_title>A Phase II Trial of Interferon Alpha-1b (IFN Alpha-1b) in Patients With Metastatic Clear Cell Renal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Interferon alfa may interfere with the growth of tumor cells and slow the growth&#xD;
      of kidney cancer.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well interferon alfa works in treating patients&#xD;
      with metastatic kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the objective response rate in patients with metastatic renal clear cell&#xD;
           carcinoma treated with interferon alfa-1b.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
      Patients receive interferon alfa-1b subcutaneously daily. Treatment continues in the absence&#xD;
      of unacceptable toxicity or disease progression.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy</measure>
  </primary_outcome>
  <enrollment type="Actual">7</enrollment>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alpha-1b</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed predominantly renal clear cell carcinoma&#xD;
&#xD;
               -  Clinical evidence of OR biopsy-proven metastatic disease to a site or sites&#xD;
                  distant from the primary tumor&#xD;
&#xD;
          -  Must have measurable disease, defined as ≥ 1 unidimensionally measurable lesion&#xD;
             measured as ≥ 20 mm with conventional techniques OR as ≥ 10 mm with spiral CT scan&#xD;
&#xD;
          -  Good- or intermediate-risk category as defined by having ≤ 2 of the following factors:&#xD;
&#xD;
               -  Time from initial diagnosis to treatment &lt; 1 year&#xD;
&#xD;
               -  Karnofsky performance status &lt; 80%&#xD;
&#xD;
               -  Hemoglobin &lt; lower limit of normal&#xD;
&#xD;
               -  Corrected calcium &gt; 10.0 mg/dL&#xD;
&#xD;
               -  Lactate dehydrogenase (LDH) &gt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  No major clinical ascites or pleural effusion&#xD;
&#xD;
          -  No CNS metastases by neurologic exam and CT scan or MRI&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9.5 g/dL&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL (2.0 mg/dL in post-nephrectomy patients)&#xD;
&#xD;
          -  Calcium normal&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  AST ≤ 3.0 times normal&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times normal (10 times ULN in presence of bone metastases)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception prior to and for the duration of&#xD;
             study treatment&#xD;
&#xD;
          -  No history of serious cardiac arrhythmia, congestive heart failure, angina pectoris,&#xD;
             or other severe cardiovascular disease (i.e., New York Heart Association class III or&#xD;
             IV)&#xD;
&#xD;
          -  No known positivity for HIV or hepatitis B surface antigen&#xD;
&#xD;
          -  No history of seizure disorders&#xD;
&#xD;
          -  No local and/or systemic infections requiring antibiotics within 28 days prior to&#xD;
             study entry&#xD;
&#xD;
          -  No other malignancy except basal cell or squamous cell carcinoma of the skin,&#xD;
             carcinoma in situ of the uterine cervix, or any malignancy treated with curative&#xD;
             intent and in complete remission for &gt; 3 years&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior organ allografts&#xD;
&#xD;
          -  No prior interferon&#xD;
&#xD;
          -  No prior cytokine-based therapy for metastatic disease&#xD;
&#xD;
          -  Prior radiotherapy is allowed for the control of pain from skeletal lesions provided&#xD;
             treatment was completed &gt; 28 days prior to study entry and patient has recovered&#xD;
&#xD;
          -  No major surgery requiring general anesthesia within 28 days prior to study entry&#xD;
&#xD;
          -  No more than 2 prior therapies for metastatic disease&#xD;
&#xD;
          -  No concurrent palliative radiotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
          -  No concurrent hormonal therapy except for hormones administered for nondisease-related&#xD;
             conditions (e.g., insulin for diabetes)&#xD;
&#xD;
          -  No concurrent steroid use except ongoing replacement therapy with physiologic doses of&#xD;
             corticosteroids&#xD;
&#xD;
               -  No concurrent dexamethasone or other steroidal anti-emetics or&#xD;
                  anti-inflammatories&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent aspirin or barbiturates&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald M. Bukowski, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>January 16, 2006</study_first_submitted>
  <study_first_submitted_qc>January 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2006</study_first_posted>
  <last_update_submitted>May 2, 2011</last_update_submitted>
  <last_update_submitted_qc>May 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Ronald M. Bukowski</name_title>
    <organization>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>clear cell renal cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon-alfa-1b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

